Rasagiline in treatment of Parkinson’s disease
نویسندگان
چکیده
منابع مشابه
Rasagiline in treatment of Parkinson’s disease
Rasagiline (N-propargyl-1 (R)-aminoindan) is a novel propargylamine, irreversible, selective monoamine oxidase inhibitor for treatment of Parkinson's disease (PD), a progressive condition associated with degeneration of dopaminergic neurons in the substantia nigra. Rasagiline inhibits striatal dopamine metabolism, thereby providing relief from motor symptoms of PD. It may be dosed once daily an...
متن کاملThe role of rasagiline in the treatment of Parkinson’s disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% to 2% of people older than 60 years. Treatment of PD consists of symptomatic therapies while neuroprotective strategies have remained elusive. Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD. Rasagiline inhibits MAO-B ...
متن کاملThe use of rasagiline in Parkinson's disease.
Rasagiline is a novel, potent, irreversible inhibitor of monoamine oxidative B developed for the symptomatic treatment of Parkinson's disease. The drug has shown efficacy in improving motor features in both early and advanced Parkinson's disease patients. The drug appears to be well tolerated and its once daily fixed dose formulation should make for excellent compliance. Rasagiline has also dem...
متن کاملRasagiline (Azilect) for Parkinson's disease.
This Medicine Update is for people with Parkinson's disease who are taking, or thinking about taking, rasagiline. Independent, not-for-profit and evidence based, NPS enables better decisions about medicines and medical tests. We are funded by the Australian Government Department of Health and Ageing. Summary Rasagiline is a medicine that has recently been made available in Australia for the tre...
متن کاملCost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
BACKGROUND The economic burden of Parkinson's disease (PD) is high, especially in patients experiencing motor fluctuations. Rasagiline has demonstrated efficacy against symptoms of PD in early and advanced stages of the disease. OBJECTIVE To assess the cost-utility of rasagiline and entacapone as adjunctive therapies to levodopa versus standard levodopa care in PD patients with motor fluctuat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuropsychiatric Disease and Treatment
سال: 2008
ISSN: 1176-6328
DOI: 10.2147/ndt.s464